Drug coverage is limited to prescription products approved by the Food and Drug Administration as evidenced by a New Drug Application (NDA), Abbreviated New Drug Application (ANDA), or Biologics Licensed Application (BLA) on file.   Any legal requirements or group specific benefits for coverage will supersede this (e.g. preventive drugs per the Affordable Care Act).

Drug coverage may also be subject to policy guidelines or exclusions established by Blue Cross and Blue Shield of Alabama. The following guidelines are meant to help members understand the requirements related to their drug coverage. These drugs may require a doctor’s request for preapproval or prior authorization.

Please note: Some employer groups may have specific drug coverage requirements for their employees that are not included in the criteria below.

*Coverage Benefit - (P) Pharmacy Benefit, (M) Medical Benefit, (B) Both

Search by Drug Name

Product Name Guideline *Coverage Benefit Implementation Date Change Date
TAFINLAR® Prior authorization for medical necessity is required. The limits are 4 capsules per day. P 01/01/14
TAFINLAR® Prior authorization for medical necessity is required. The limits are 4 capsules per day. P 01/01/14
TAGRISSO Prior authorization for medical necessity is required. Limits are 30 tablets per 30 days. P 11/25/15 01/01/16
TAGRISSO Prior authorization for medical necessity is required. Limits are 30 tablets per 30 days. P 11/25/15 01/01/16
TALACEN The limits are 180 tablets per 30 days. P 04/01/12
TALACEN The limits are 180 tablets per 30 days. P 04/01/12
TALTZ™ Taltz may be subject to step therapy requirements. Patients must have trial and failure of two preferred products. Preferred products are Humira, Enbrel, Stelara and Simponi. The limits are 1 syringe per day. P 04/15/16
TAMIFLU® The limits are 20 capsules per 30 days for Tamiflu 30mg, 10 capsules per 30 days for Tamiflu 35mg and 75mg, and 180 mL per 30 days for Tamiflu 6mg/mL oral suspension. P 02/01/05 07/01/13
TAMIFLU® The limits are 20 capsules per 30 days for Tamiflu 30mg, 10 capsules per 30 days for Tamiflu 35mg and 75mg, and 180 mL per 30 days for Tamiflu 6mg/mL oral suspension. P 02/01/05 07/01/13
TANZEUM® Tanzeum may be subject to step therapy requirements. Patients must have trial and failure of one or more of the following antidiabetic agents: metformin, sulfonylurea, combinations of metformin or sulfonylureas, or basal insulin (Lantus or Levemir). The limits are 4 vials per 28 days. P 10/01/14
TANZEUM® Tanzeum may be subject to step therapy requirements. Patients must have trial and failure of one or more of the following antidiabetic agents: metformin, sulfonylurea, combinations of metformin or sulfonylureas, or basal insulin (Lantus or Levemir). The limits are 4 vials per 28 days. P 10/01/14
TARCEVA® Prior authorization for medical necessity is required. The limits are 1 tablet per day, except 25mg tablets with a limit of 2 tablets per day. P 03/14/07 07/01/11
TARCEVA® Prior authorization for medical necessity is required. The limits are 1 tablet per day, except 25mg tablets with a limit of 2 tablets per day. P 03/14/07 07/01/11
TARGADOX® Targadox may be subject to step therapy requirements. Patients must have trial and failure of generic immediate release doxycycline AND immediate release minocycline. P 06/21/15
TARGADOX® Targadox may be subject to step therapy requirements. Patients must have trial and failure of generic immediate release doxycycline AND immediate release minocycline. P 06/21/15